ERBB2 and breast cancer: Prior to the advent of trastuzumab, a monoclonal antibody directed against the extra-cellular domain of the HER-2 receptor, the HER-2-positive subtype of breast cancer was associated with a worst prognosis compared to other subtypes of breast cancer [1, 2].